Results 31 to 40 of about 289,700 (218)

Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3 [PDF]

open access: yes, 1992
To reduce the opportunities for human immunodeficiency virus type 1 (HIV-1) to evade vaccine induced immunity, the development of subunit vaccines must focus on the characterization of immunogenic epitopes, which are major targets for the immune system ...
Böltz, T.   +6 more
core   +5 more sources

Natural autoantibodies in healthy neonatals recognizing a peptide derived from the second conserved region of HIV-1 GP120 [PDF]

open access: yesVojnosanitetski Pregled, 2014
Background/Aim. High sera reactivity with a peptide derived from human immunodeficiency virus HIV-1 envelope protein gp120, NTM1, correlate with non-progressive HIV-1 infection and also may have protective role in breast and prostate cancer.
Đorđević-Vujičić Ana   +4 more
doaj   +1 more source

Geographic and Temporal Variability of Hepatitis E Virus Circulation in the Russian Federation

open access: yesViruses, 2022
The factors influencing hepatitis E virus (HEV) circulation remain largely unexplored. We investigated HEV seroprevalence in humans and the prevalence of infection in farm pigs and rabbits in different regions of the Russian Federation, as well as the ...
Mikhail I. Mikhailov   +20 more
doaj   +1 more source

Design and expression of TolC as a recombinant protein vaccine against Shigella flexneri and evaluation of immunogenic response in mice [PDF]

open access: yesarXiv, 2023
Background: Shigella is one of the major cause of dysenteric diarrhea, which is known shigelosis. Shigelosis causes 160,000 deaths annually of diarrheal disease in a global scale especially children less than 5 years old. No licensed vaccine is available against shigelosis, therefore, efforts for develop an effective and safe vaccine against shigella ...
arxiv  

Complement-Mediated Virus Infectivity Neutralisation by HLA Antibodies Is Associated with Sterilising Immunity to SIV Challenge in the Macaque Model for HIV/AIDS. [PDF]

open access: yes, 2014
Sterilising immunity is a desired outcome for vaccination against human immunodeficiency virus (HIV) and has been observed in the macaque model using inactivated simian immunodeficiency virus (SIV).
A Morner   +61 more
core   +5 more sources

ROC-Analysis of the Results as regards B. pseudomallei and B. mallei Agents Detection Using Solid-Phase ELISA

open access: yesПроблемы особо опасных инфекций, 2013
Analyzed are operational characteristic curves (ROC-curves) of solid-phase ELISA variants with immune sera to cellular and extracellular Burkholderia antigens with the aim to determine the most effective ones for B. pseudomallei and
A. A. Budchenko   +3 more
doaj   +1 more source

Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes

open access: yesVaccines, 2021
Many of the approved SARS-CoV-2 vaccines are based on a stabilized variant of the spike protein. This raises the question of whether the immune response against the stabilized spike is identical to the immune response that is elicited by the native spike
Sascha Hein   +8 more
doaj   +1 more source

A novel Galleria mellonella experimental model for zoonotic pathogen Brucella

open access: yesVirulence, 2023
Brucellosis is a major threat to public health and animal husbandry. Several in vivo vertebrate models, such as mice, guinea pigs, and nonhuman primates, have been used to study Brucella pathogenesis, bacteria-host interactions, and vaccine efficacy ...
Shuyi Wang   +11 more
doaj   +1 more source

$L^2$-Riemann-Roch for singular complex curves [PDF]

open access: yesJournal of Singularities 11 (2015), 67-84, 2013
We present a comprehensive $L^2$-theory for the $\overline\partial$-operator on singular complex curves, including $L^2$-versions of the Riemann-Roch theorem and some applications.
arxiv   +1 more source

Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis

open access: yesFrontiers in Immunology, 2018
A Phase 1b/2a clinical trial of NDV-3A vaccine containing a Candida albicans recombinant Als3 protein formulated with alum protected women <40 years old from recurrent vulvovaginal candidiasis (RVVC).
Priya Uppuluri   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy